Nkarta Inc. (NKTX)
NASDAQ: NKTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NKTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $81.29M
- EPS (TTM)
- -$1.73
- Dividend yield
- None
- 52-week range
- 1.11 – 3.72
- Day range
- 1.11 – 1.22
- Volume / Avg
- 1.60M / 1.02M
- Beta
- —
- Shares outstanding
- 71.62M
52-week range
NKTX stock today
Shares of Nkarta (NKTX) finished higher on Nov 20 at $1.14, a gain of 1.34% or $0.015 per share, versus the S&P 500's 3.70% decline. Shares are 69.5% below their 52-week high of $3.72, set on Jul 9, 2026 and 2.7% above the 52-week low of $1.11, near the bottom of the past year's range. NKTX is down 38.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 36.9%.
Nkarta has posted a net loss over the last twelve months (EPS of -$1.73), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Nkarta
Company profileNkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Paul J. Hastings
- Headquarters
- South San Francisco, CA
- Employees
- 108
- IPO year
- 2020
- Website
- nkartatx.com
Financial highlights
Full financialsIn fiscal 2025, Nkarta generated $0 in revenue, up 0.0% from fiscal 2024. Nkarta reported a net loss of $104.1 million, compared with a loss of $108.8 million a year earlier. Diluted earnings per share came in at -$1.41.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-104.08M | $-108.79M | $-117.50M | $-113.84M | $-86.08M |
| EPS (diluted) | $-1.41 | $-1.60 | $-2.40 | $-2.61 | $-2.62 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$10.50+825.11%
- Strong buy 1
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.45 vs $-0.40
- Surprise
- -12.50%
NKTX news
All NKTX news- Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026GlobeNewswire
- Nkarta, Inc. Announces Initial Clinical Data for NKX019 in Myositis and Systemic SclerosisNasdaqNKTX, ET
- Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR ConvergenceGlobeNewswire
- Nkarta, Inc. to Host Webcast to Discuss Initial Clinical Data for NKX019 at ACR Convergence 2026Nasdaq
- Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026GlobeNewswire
- Nkarta Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
Nkarta peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TLSATiziana Life Sciences Ltd. | 0.6206 | -8.14% | $79.45M | vs NKTX |
| HURATuHURA Biosciences Inc. | 1.25 | -8.09% | $82.20M | vs NKTX |
| OGIOrganigram Global Inc. | 0.583 | -7.40% | $82.27M | vs NKTX |
| ANIXAnixa Biosciences Inc. | 2.44 | -6.15% | $84.82M | vs NKTX |
| UPBUpstream Bio Inc. | 1.59 | -20.50% | $87.15M | vs NKTX |
| EQEquillium Inc. | 1.06 | -5.36% | $87.26M | vs NKTX |
| RTSNRetension Pharmaceuticals Inc. | 10.51 | -19.22% | $87.57M | vs NKTX |
| CPIXCumberland Pharmaceuticals Inc. | 5.84 | -7.30% | $87.57M | vs NKTX |
Indexes, lists and sector
Nkarta stock FAQ
What is Nkarta's stock price today?
NKTX last traded at $1.14 as of Nov 20, 4:00 PM EST, up 1.34% on the day. Prices are delayed at least 15 minutes.
Who is Nkarta's CEO?
Mr. Paul J. Hastings is the chief executive officer of Nkarta Inc., which has about 108 employees.
What is the NKTX 52-week high?
The 52-week high for NKTX is $3.72 and the 52-week low is $1.11. The stock is currently 69.5% below its high.